As of January, 31, 2019 PDI is no longer a Publicis Health/Publicis Groupe company. Look for all our new branding soon!


The quality of rheumatology care is increasingly measured through patient- related outcomes. Optimizing these outcomes means providing patients with rheumatologic and musculoskeletal diseases access to disease-modifying antirheumatic drugs.

Giving patients access to disease-modifying antirheumatic drugs (DMARDs) while controlling their cost requires a twofold approach. Rheumatologists face cost-control pressures because of both the high price of DMARDs and the difficulty with objectively documenting treatment outcomes.

First, cost control for DMARD treatment can be achieved through dose reductions for patients in remission. Second, outcomes documentation is critical to reimbursement and patient access to treatment. However, objectively documenting the outcomes of rheumatology care is difficult because universally accepted outcome measures do not exist. In principle, outcomes could be measured through radiography, clinical scores, or functional status, but patient-reported outcomes are becoming ever more important.

PDI can collaborate with you to build pharmaceutical sales strategies that help your target healthcare professionals (HCPs) achieve optimal patient outcomes while controlling cost.

PDI stands ready to develop pharmaceutical sales strategies that enable rheumatologists to optimize patient outcomes at acceptable costs. Our field-based and inside medical sales representatives are at the center of such strategies by providing prescriber education while helping your rheumatology customers find ways to maintain or increase the economic viability of their practices. Our medical science liaisons (MSLs) can engage with key opinion leaders in rheumatology and offer expert education to clinicians. Our clinical health educators (CHEs) can work with patients and caregivers to significantly improve outcomes.

Rheumatologists and primary care providers treating patients with rheumatologic and musculoskeletal diseases can benefit from help aimed at maximizing patient outcomes while also delivering care at acceptable costs:

  • Education on RMDs for primary care providers
  • Education on efficacy and dosing of DMARDs
  • Differentiation of safety, efficacy, and costs between biologic and biosimilar DMARDs
  • Guidance on how to engage patients in the management of their disease to increase treatment adherence and enable improved patient outcomes

Learn how we can assist your rheumatology customers deliver state-of-the-art-care

Contact Us Now